Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#31 / 74 Total
GRRR - Gorilla Technology Group Inc - Stock Price Chart
TickerGRRR [NASD]
CompanyGorilla Technology Group Inc
CountryUnited Kingdom
IndustrySoftware - Infrastructure
Market Cap49.94MEPS (ttm)-
P/E-EPS this Y-115.60%
Forward P/E-EPS next Y48.72%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B8.27EPS Q/Q305.79%
Dividend-Sales Q/Q97.64%
Insider Own34.49%Inst Own2.18%
Insider Trans0.00%Inst Trans-
Short Float8.10%EarningsApr 08/b
Analyst Recom1.00Target Price43.00
Avg Volume316.38K52W Range4.79 - 69.80
Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.
DRMA - Dermata Therapeutics Inc - Stock Price Chart
TickerDRMA [NASD]
CompanyDermata Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.42MEPS (ttm)-0.27
P/E-EPS this Y48.31%
Forward P/E-EPS next Y52.17%
PEG-EPS past 5Y26.37%
P/S-EPS next 5Y-
P/B3.36EPS Q/Q74.96%
Dividend-Sales Q/Q-
Insider Own6.04%Inst Own4.06%
Insider Trans0.00%Inst Trans-85.42%
Short Float1.28%EarningsMar 22/b
Analyst Recom1.00Target Price337.50
Avg Volume7.98K52W Range3.48 - 42.15
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.
NRXP - NRX Pharmaceuticals Inc - Stock Price Chart
TickerNRXP [NASD]
CompanyNRX Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap33.88MEPS (ttm)-2.11
P/E-EPS this Y45.50%
Forward P/E-EPS next Y3.67%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-350.73%
Dividend-Sales Q/Q-
Insider Own17.80%Inst Own4.06%
Insider Trans0.00%Inst Trans-
Short Float6.18%EarningsMay 14/a
Analyst Recom1.00Target Price50.00
Avg Volume438.26K52W Range1.90 - 12.00
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hurvitz ChaimDirectorAug 30 '23Buy0.2970,00020,125570,000Sep 11 09:15 AM
Gorovitz AaronDirectorAug 30 '23Buy0.3235,00011,196105,000Sep 11 09:19 AM
Javitt Jonathan CChief ScientistAug 23 '23Buy0.33100,00033,000446,332Aug 24 12:14 PM
Javitt Jonathan CChief ScientistAug 22 '23Buy0.32200,00064,400346,332Aug 23 09:24 AM
EXTR - Extreme Networks Inc. - Stock Price Chart
TickerEXTR [NASD, RUT]
CompanyExtreme Networks Inc.
CountryUSA
IndustryCommunication Equipment
Market Cap1.54BEPS (ttm)-0.06
P/E-EPS this Y-51.51%
Forward P/E16.03EPS next Y40.24%
PEG-EPS past 5Y-
P/S1.26EPS next 5Y20.00%
P/B23.75EPS Q/Q-399.46%
Dividend-Sales Q/Q-36.53%
Insider Own2.72%Inst Own94.60%
Insider Trans-2.94%Inst Trans3.31%
Short Float9.67%EarningsMay 01/b
Analyst Recom2.14Target Price14.58
Avg Volume2.16M52W Range10.49 - 32.73
TodayUpgrade Craig Hallum Hold → Buy $14
Extreme Networks, Inc. engages in the provision of software driven networking solutions for enterprise, data center, and service provider customers. It operates through the following geographical segments: Americas, EMEA, and APAC. Its products include Extreme Applications, Extreme Switching, Extreme Routing and Extreme Mobility. The company was founded in May 1996 and is headquartered in Morrisville, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MEYERCORD EDWARDPRESIDENT AND CEOMay 09 '24Sale10.6350,000531,3701,119,724May 10 04:11 PM
MOTIEY KATAYOUNChief Legal Admin Sust OfficerFeb 15 '24Option Exercise0.009,4980104,405Feb 16 04:19 PM
MEYERCORD EDWARDPRESIDENT AND CEOFeb 15 '24Option Exercise0.0064,72701,184,942Feb 16 04:18 PM
MEYERCORD EDWARDPRESIDENT AND CEOFeb 01 '24Option Exercise6.4028,443182,0351,158,054Feb 02 05:03 PM
MEYERCORD EDWARDPRESIDENT AND CEOFeb 01 '24Sale13.2428,443376,6021,129,611Feb 02 05:03 PM
INVO - INVO Bioscience Inc - Stock Price Chart
TickerINVO [NASD]
CompanyINVO Bioscience Inc
CountryUSA
IndustryMedical Devices
Market Cap3.21MEPS (ttm)-8.66
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y17.42%
P/S1.06EPS next 5Y-
P/B-EPS Q/Q82.40%
Dividend-Sales Q/Q396.78%
Insider Own0.96%Inst Own4.08%
Insider Trans0.00%Inst Trans-24.87%
Short Float1.21%EarningsApr 16/b
Analyst Recom3.00Target Price2.00
Avg Volume3.93M52W Range0.50 - 8.60
INVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.
IMPP - Imperial Petroleum Inc - Stock Price Chart
TickerIMPP [NASD]
CompanyImperial Petroleum Inc
CountryGreece
IndustryOil & Gas Midstream
Market Cap113.57MEPS (ttm)36.64
P/E0.11EPS this Y-63.43%
Forward P/E3.50EPS next Y14.29%
PEG-EPS past 5Y-
P/S0.62EPS next 5Y-
P/B0.32EPS Q/Q-128.98%
Dividend-Sales Q/Q-21.19%
Insider Own40.03%Inst Own4.66%
Insider Trans0.00%Inst Trans83.60%
Short Float22.49%EarningsMay 16/b
Analyst Recom1.00Target Price8.00
Avg Volume488.27K52W Range1.18 - 4.08
Imperial Petroleum, Inc. operates as a ship-owning company. It provides petroleum product and crude oil seaborne transportation services. The firm offers international seaborne transportation services to oil producers, refineries and commodities traders. It has a fleet of three medium range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals, and one Aframax tanker which is used for carrying crude oil. The company was founded on May 14, 2021 and is headquartered in Athens, Greece.
CGC - Canopy Growth Corporation - Stock Price Chart
TickerCGC [NASD]
CompanyCanopy Growth Corporation
CountryCanada
IndustryDrug Manufacturers - Specialty & Generic
Market Cap983.90MEPS (ttm)-16.06
P/E-EPS this Y90.69%
Forward P/E-EPS next Y84.69%
PEG-EPS past 5Y-76.81%
P/S4.02EPS next 5Y13.28%
P/B2.17EPS Q/Q51.57%
Dividend-Sales Q/Q-22.69%
Insider Own28.90%Inst Own6.03%
Insider Trans-0.39%Inst Trans-
Short Float13.32%EarningsFeb 09/b
Analyst Recom3.62Target Price6.03
Avg Volume16.00M52W Range2.76 - 19.20
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lazzarato David AngeloDirectorDec 29 '23Sale6.683,71324,80317,042Jan 02 06:33 PM
Yanofsky TheresaDirectorDec 29 '23Sale6.683,69724,69617,501Jan 02 06:34 PM
Lazzarato David AngeloDirectorNov 20 '23Sale0.8138,50231,187207,562Nov 22 04:03 PM
Yanofsky TheresaDirectorNov 20 '23Sale0.8138,34431,059211,991Nov 22 04:02 PM
SCHMELING JUDYDirectorNov 20 '23Sale0.8118,48114,970420,541Nov 22 04:01 PM
LIDR - AEye Inc - Stock Price Chart
TickerLIDR [NASD]
CompanyAEye Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap23.65MEPS (ttm)-11.56
P/E-EPS this Y37.66%
Forward P/E-EPS next Y5.10%
PEG-EPS past 5Y-657.36%
P/S27.83EPS next 5Y-
P/B1.08EPS Q/Q66.14%
Dividend-Sales Q/Q-96.86%
Insider Own17.06%Inst Own8.25%
Insider Trans-44.57%Inst Trans-
Short Float3.95%EarningsMay 14/a
Analyst Recom3.00Target Price1.20
Avg Volume3.69M52W Range0.92 - 24.00
AEye, Inc. engages in the development of vision hardware, software and algorithms that act as the eyes and visual cortex of autonomous vehicles. It specializes in computer vision, autonomous driving, robotic vision, autonomous vehicles, lidar, sensor fusion, and three dimensional mapping. The company was founded by Luis C. Dussan, Ranson Wuller, Barry Behnken, and Jordan Greene in 2013 and is headquartered in Dublin, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dussan LuisDirectorDec 01 '23Sale0.1532,7784,94616,344,985Dec 01 06:07 PM
Dussan LuisDirectorNov 30 '23Sale0.1564,1099,88616,377,763Dec 01 06:07 PM
Dussan LuisDirectorNov 29 '23Sale0.1587,05413,32816,441,872Nov 29 05:54 PM
Dussan LuisDirectorNov 28 '23Sale0.1655,2338,56716,528,926Nov 29 05:54 PM
Dussan LuisDirectorNov 27 '23Sale0.1649,8528,10616,584,159Nov 27 05:35 PM
VTYX - Ventyx Biosciences Inc - Stock Price Chart
TickerVTYX [NASD, RUT]
CompanyVentyx Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap321.83MEPS (ttm)-3.24
P/E-EPS this Y22.32%
Forward P/E-EPS next Y1.17%
PEG-EPS past 5Y-148.81%
P/S-EPS next 5Y-
P/B1.05EPS Q/Q7.64%
Dividend-Sales Q/Q-
Insider Own19.36%Inst Own73.49%
Insider Trans-0.66%Inst Trans7.14%
Short Float14.79%EarningsMay 09/a
Analyst Recom1.67Target Price9.33
Avg Volume3.92M52W Range1.87 - 40.58
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohan RajuCEO AND PRESIDENTApr 02 '24Sale5.404,31223,2991,578,250Apr 03 07:32 PM
Krueger Christopher WCHIEF BUSINESS OFFICERApr 02 '24Sale5.401,6518,921284,999Apr 03 07:37 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERApr 02 '24Sale5.401,6518,921264,998Apr 03 07:33 PM
Auster MartinCHIEF FINANCIAL OFFICERApr 02 '24Sale5.401,4057,59224,303Apr 03 07:30 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERMar 28 '24Option Exercise0.004,5310266,649Mar 29 06:07 PM
ALLK - Allakos Inc - Stock Price Chart
TickerALLK [NASD, RUT]
CompanyAllakos Inc
CountryUSA
IndustryBiotechnology
Market Cap114.22MEPS (ttm)-2.45
P/E-EPS this Y28.45%
Forward P/E-EPS next Y52.82%
PEG-EPS past 5Y0.51%
P/S-EPS next 5Y26.70%
P/B1.10EPS Q/Q-63.58%
Dividend-Sales Q/Q-
Insider Own14.53%Inst Own75.40%
Insider Trans0.00%Inst Trans63.92%
Short Float7.39%EarningsMay 09/a
Analyst Recom2.50Target Price2.90
Avg Volume552.41K52W Range0.98 - 5.64
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
12345678